Sign in
CompletedNo phase

Gestational Diabetes and Antenatal Human Milk Expression

Key facts

Who runs it
The University of Hong Kong
Where
Hong Kong2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
246 people enrolled
Started
10 May 2023
Ended
10 May 2024
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Antenatal milk expression and breastfeeding self-efficacy enhancement
Record updated
19 September 2024

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • diagnosed gestational diabetes without on insulin
  • can read and speak Chinese
  • Hong Kong resident and stay in Hong Kong after delivery
  • no serious medical or obstetrical complications
  • no mental health illness or history
  • have regular antenatal check-up
  • singleton pregnancy
  • primiparous or multiparous women
  • intention to breastfeed
  • pre-pregnancy BMI<25

Who cannot take part

  • do not have Hong Kong Identify Card
  • breastfeeding elder child at pregnancy
  • cannot understand the study
  • give birth <37 weeks of gestation
  • a known fetal anomaly or any suspicion of fetal compromise

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Exclusive breastfeeding is global recognized as the optimal infant feeding. Hong Kong is committed to promoting, protecting and supporting the global movement for successful breastfeeding. Exclusive breastfeeding is especially strongly recommended and supported to the maternal history of Gestational Diabetes Mellitus (GDM). This study aims to examine the acceptability and feasibility of Antenatal human milk expression (AME) as breastfeeding intervention to improve breastfeeding for GDM women. The efficacy of AME practice on the breastfeeding exclusivity will also be investigated. It is hypothesized that AME will increase breastfeeding exclusivity compare with women receiving standard care, and will improve the breastfeeding self-efficacy and reduce depressive symptoms of women after birth.

The 2 groups in the trial

  • Standard care plus an antenatal milk expression educationTreatment being tested

    Participants will have one face-to-face breastfeeding education in lactation clinic at 37 weeks of gestation and telephone follow-up weekly till delivery.

    Treatment: Antenatal milk expression and breastfeeding self-efficacy enhancement

  • Standard hospital antenatal careNo study treatment, for comparison

    Participants will receive standard care include prenatal breastfeeding education at gestation of 24-36 weeks same as intervention group. They will not discuss about antenatal milk expression, breastfeeding self-efficacy and the effects of breastfeeding on GDM women.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Effects and Experience of a Gestational Diabetes and Antenatal Human Milk Expression (GAME) Programme in Hong Kong Chinese Women
Publications
Record updated
19 September 2024